All In Biotech

Drug Trial Radar · NCT00751621

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (IgPro20 EU Extension Study)

Last checked: Nov 19, 2026Latest source record: Apr 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

40

Actual

Start

Aug 2008

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Sep 12, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a continuation of the study ZLB06\_001CR with the objective of assessing efficacy, tolerability, safety of IgPro, as well as long-term health-related quality of life in patients with PID.

Conditions

  • Primary Immunodeficiency (PID)

Interventions

  • IgPro20Biological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Serum IgG Trough LevelsTime frame: Up to 42 months

Locations

13 sites in 8 countries. Site status is shown where the registry gives one.

  • Study Site

    Paris, France

  • Study Site

    Berlin, Germany

  • Study Site

    Freiburg im Breisgau, Germany

  • Study Site

    Leipzig, Germany

  • Study Site

    Mainz, Germany

  • Study Site

    Warsaw, Poland

  • Study Site

    Cluj-Napoca, Romania

  • Study Site

    Timișoara, Romania

  • Study Site

    Barcelona, Spain

  • Study Site

    Seville, Spain

  • Study Site

    Gothenburg, Sweden

  • Study Site

    Bern, Switzerland

  • Study Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.